Moxetumomab pasudotox
Capillary Leak Syndrome and Hemolytic Uremic Syndrome
Capillary Leak Syndrome (CLS)
- Capillary Leak Syndrome (CLS), including life-threatening cases, occurred in patients receiving LUMOXITI. Delay dosing or discontinue LUMOXITI as recommended.
Hemolytic Uremic Syndrome (HUS)
- Hemolytic Uremic Syndrome (HUS), including life-threatening cases, occurred in patients receiving LUMOXITI. Discontinue LUMOXITI in patients with HUS.
Patient Counseling Information
Medication Guides
Package Inserts
Updated December 2018